| |
| |
|
| Insider
Information: |
Gibson Neil W |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
52,745 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
52,745 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
6
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
6.0
|
| Percentage
Gain/Loss : |
0.0%
|
 2,190.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regulus Therapeutics Inc. |
RGLS |
Chief Scientific Officer |
2015-01-28 |
0 |
2013-02-04 |
0 |
Premium* |
|
|
Tcr2 Therapeutics Inc. |
TCRR |
Director |
2019-02-19 |
0 |
2020-03-20 |
0 |
Premium* |
|
|
Shattuck Labs, Inc. |
STTK |
Director |
2020-10-08 |
52,745 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| STTK |
Shattuck Labs, Inc. |
Director |
– • – |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
52,745 |
|
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
Director |
– • – |
2020-03-20 |
4 |
S |
$7.94 |
$5,145 |
I/I |
(648) |
0 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
Director |
– • – |
2020-03-19 |
4 |
S |
$7.41 |
$23,267 |
I/I |
(3,140) |
648 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
Director |
– • – |
2020-03-18 |
4 |
S |
$6.83 |
$21,310 |
I/I |
(3,120) |
3,788 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
Director |
– • – |
2020-03-17 |
4 |
S |
$6.49 |
$19,528 |
I/I |
(3,009) |
6,908 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
Director |
– • – |
2020-03-16 |
4 |
S |
$6.60 |
$117,043 |
I/I |
(17,723) |
9,917 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
Director |
– • – |
2020-03-13 |
4 |
S |
$6.52 |
$338,894 |
I/I |
(52,000) |
27,640 |
0 |
% |
|
| TCRR |
Tcr2 Therapeutics Inc. |
Director |
– • – |
2019-11-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(217,974) |
79,640 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
Director |
– • – |
2019-11-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(196,177) |
297,614 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
Director |
– • – |
2019-11-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(212,560) |
493,791 |
0 |
- |
|
| TCRR |
Tcr2 Therapeutics Inc. |
Director |
– • – |
2019-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
706,351 |
706,351 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2015-01-28 |
4 |
AS |
$17.98 |
$1,444,304 |
D/D |
(80,000) |
0 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-11-28 |
4 |
AS |
$18.80 |
$48,245 |
D/D |
(2,500) |
80,000 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-11-28 |
4 |
OE |
$1.74 |
$4,350 |
D/D |
2,500 |
82,500 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-10-29 |
4 |
AS |
$18.68 |
$48,234 |
D/D |
(2,500) |
80,000 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-10-29 |
4 |
OE |
$1.74 |
$4,350 |
D/D |
2,500 |
82,500 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-10-22 |
4 |
AS |
$14.44 |
$47,644 |
D/D |
(3,300) |
80,000 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-10-22 |
4 |
OE |
$1.74 |
$5,742 |
D/D |
3,300 |
83,300 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-09-12 |
4 |
AS |
$8.01 |
$17,617 |
D/D |
(2,200) |
80,000 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-09-12 |
4 |
OE |
$1.74 |
$3,828 |
D/D |
2,200 |
82,200 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-09-11 |
4 |
AS |
$8.01 |
$16,010 |
D/D |
(2,000) |
80,000 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-09-11 |
4 |
OE |
$1.74 |
$3,480 |
D/D |
2,000 |
82,000 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-07-01 |
4 |
AS |
$8.10 |
$20,260 |
D/D |
(2,500) |
80,000 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-07-01 |
4 |
OE |
$1.74 |
$4,350 |
D/D |
2,500 |
82,500 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Scientific Officer |
• – – |
2014-06-17 |
4 |
OE |
$1.74 |
$8,700 |
D/D |
5,000 |
85,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
